9,582 BioMarin Pharmaceutical Inc. $BMRN Shares Acquired by Profund Advisors LLC

Profund Advisors LLC raised its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) by 34.3% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 37,548 shares of the biotechnology company’s stock after purchasing an additional 9,582 shares during the quarter. Profund Advisors LLC’s holdings in BioMarin Pharmaceutical were worth $2,253,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Primecap Management Co. CA acquired a new position in BioMarin Pharmaceutical in the 2nd quarter worth $811,962,000. Dimensional Fund Advisors LP grew its stake in shares of BioMarin Pharmaceutical by 14.5% during the first quarter. Dimensional Fund Advisors LP now owns 3,802,930 shares of the biotechnology company’s stock valued at $214,804,000 after acquiring an additional 481,176 shares in the last quarter. First Trust Advisors LP grew its stake in shares of BioMarin Pharmaceutical by 43.3% during the first quarter. First Trust Advisors LP now owns 1,672,491 shares of the biotechnology company’s stock valued at $94,479,000 after acquiring an additional 505,692 shares in the last quarter. Caisse de depot et placement du Quebec purchased a new stake in shares of BioMarin Pharmaceutical during the second quarter worth about $70,749,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of BioMarin Pharmaceutical during the second quarter worth about $66,107,000. Institutional investors and hedge funds own 98.71% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on BMRN shares. Oppenheimer boosted their price target on BioMarin Pharmaceutical from $95.00 to $97.00 and gave the stock an “outperform” rating in a research note on Friday, August 7th. William Blair upgraded BioMarin Pharmaceutical to a “hold” rating in a research note on Wednesday, September 23rd. BMO Capital Markets restated an “outperform” rating on shares of BioMarin Pharmaceutical in a report on Wednesday, September 16th. Morgan Stanley dropped their price objective on BioMarin Pharmaceutical from $124.00 to $122.00 and set an “overweight” rating on the stock in a report on Wednesday, October 21st. Finally, Piper Sandler upped their target price on BioMarin Pharmaceutical from $88.00 to $90.00 and gave the company an “overweight” rating in a research report on Tuesday, September 1st. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, BioMarin Pharmaceutical currently has a consensus rating of “Moderate Buy” and a consensus target price of $88.38.

BioMarin Pharmaceutical Stock Performance

Shares of BioMarin Pharmaceutical stock opened at $58.51 on Monday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.32 and a current ratio of 2.39. BioMarin Pharmaceutical Inc. has a 1 year low of $49.26 and a 1 year high of $70.98. The firm’s 50-day simple moving average is $60.62 and its 200-day simple moving average is $58.44. The firm has a market cap of $11.33 billion, a PE ratio of 158.14, a price-to-earnings-growth ratio of 0.64 and a beta of 0.21.

BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, topping analysts’ consensus estimates of $0.95 by $0.25. The business had revenue of $989.71 million during the quarter, compared to the consensus estimate of $932.03 million. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%. The company’s revenue for the quarter was up 20.0% compared to the same quarter last year. During the same period last year, the firm earned $1.44 earnings per share. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Equities analysts forecast that BioMarin Pharmaceutical Inc. will post 2.59 earnings per share for the current fiscal year.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company’s research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.

BioMarin’s marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.